Rita Balice-Gordon
Director/Board Member at COLLEGIUM PHARMACEUTICAL, INC.
Net worth: 930 748 $ as of 31/03/2024
Profile
Rita Balice-Gordon is currently the Chief Executive Officer & Director at Muna Therapeutics ApS, an Independent Director at Collegium Pharmaceutical, Inc., and a Director at Capsida Biotherapeutics, Inc. She previously worked as the President-Neuroscience & Pain Research Unit at Pfizer Inc., the Global Head-Rare & Neurological Diseases at Sanofi, Inc., and as a Professor at Perelman School of Medicine.
Dr. Balice-Gordon completed her undergraduate degree at Northwestern University and her doctorate at The University of Texas at Austin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 27/03/2024 | 23,976 ( 0.08% ) | 930 748 $ | 31/03/2024 |
Rita Balice-Gordon active positions
| Companies | Position | Start |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Director/Board Member | 24/09/2020 |
Muna Therapeutics ApS
 Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Chief Executive Officer | - |
Capsida Biotherapeutics, Inc.
 Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Director/Board Member | 12/05/2021 |
Former positions of Rita Balice-Gordon
| Companies | Position | End |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
| Perelman School of Medicine | Corporate Officer/Principal | - |
Sanofi, Inc.
 Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a private company based in New York, NY. | Corporate Officer/Principal | - |
Training of Rita Balice-Gordon
| Northwestern University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Sanofi, Inc.
Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a private company based in New York, NY. | Retail Trade |
Muna Therapeutics ApS
Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Health Services |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Commercial Services |
- Stock Market
- Insiders
- Rita Balice-Gordon
